Tumor suppressor candidate gene, NDRG2 is frequently inactivated in human glioblastoma multiforme

Bin Zhou1, Zhuo Tang1, Yanchun Deng1

  • 1Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.

Insights

N-myc downstream regulated gene 2 (NDRG2) expression is reduced in human glioma, correlating negatively with tumor grade. Aberrant promoter methylation likely causes this NDRG2 downregulation, impacting glioma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • N-myc downstream regulated gene 2 (NDRG2) is frequently downregulated in various cancers.
  • Understanding NDRG2's role in glioma is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate NDRG2 expression in human glioma.
  • To explore the relationship between NDRG2 expression and glioma grade.
  • To elucidate the regulatory mechanisms, specifically promoter methylation, underlying NDRG2 downregulation in glioma.

Main Methods:

  • Quantitative polymerase chain reaction (qPCR) for mRNA expression analysis.
  • Immunohistochemistry and western blot for protein expression assessment.
  • Bisulfite sequencing to determine NDRG2 promoter methylation status.

Main Results:

  • NDRG2 mRNA and protein levels were significantly lower in glioma tissues compared to adjacent normal tissues.
  • A significant negative correlation was observed between glioma tumor grade and NDRG2 expression.
  • Glioma tissues exhibited a higher NDRG2 promoter methylation rate (46.3%) than normal tissues (18.2%).

Conclusions:

  • NDRG2 expression is downregulated in human glioma, with levels inversely proportional to tumor grade.
  • Aberrant methylation of the NDRG2 promoter region is a likely mechanism for its transcriptional inactivation in glioma.
  • NDRG2 downregulation may contribute to glioma pathogenesis and progression.